Literature DB >> 8707399

Inhibition of aldosterone production by adrenomedullin, a hypotensive peptide, in the rat.

T Yamaguchi1, K Baba, Y Doi, K Yano, K Kitamura, T Eto.   

Abstract

Recently, we conducted in vitro studies and reported that adrenomedullin, a novel hypotensive peptide, inhibits aldosterone secretion by dispersed rat adrenal zona glomerulosa cells. To assess the physiological role of this inhibitory effect, we investigated the effect of adrenomedullin on aldosterone production in vivo. Male Sprague-Dawley rats were fed a normal sodium diet before the experiments. To begin the experimental procedure, we stimulated aldosterone production with a sodium-deficient diet or bilateral nephrectomy. After 3 days of sodium depletion or immediately after nephrectomy, we injected synthetic human adrenomedullin (2.5 nmol/kg SC) and repeated the injection three times at 6-hour intervals. Two hours after the last injection, the rats were decapitated and adrenal capsular tissue was collected. Adrenomedullin had no effect on plasma and adrenal aldosterone concentrations in the rats fed a normal sodium diet. Rats fed a sodium-deficient diet had significantly increased aldosterone concentrations in both plasma (4770.1 +/- 364.3 pmol/L) and adrenal gland (57.34 +/- 3.27 pmol per adrenal). Subsequently, injection of adrenomedullin significantly inhibited increases in concentrations (plasma, 2648.9 +/- 313.2 pmol/L; adrenal, 44.28 +/- 4.94 pmol per adrenal). In nephrectomized rats, increased aldosterone concentrations in plasma and adrenal gland were also significantly inhibited by adrenomedullin. In the second part of the study, plasma renin concentration, adrenal renin activity, plasma corticosterone concentration, serum potassium concentration, and plasma immunoreactive adrenomedullin concentration were examined for adrenomedullin effects. The first four were unaffected, and the last, plasma immunoreactive adrenomedullin, was elevated 15% to 30%. These in vivo results, together with our in vitro data, suggest that adrenomedullin may indeed play a physiological role in the control of blood pressure and electrolyte balance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707399     DOI: 10.1161/01.hyp.28.2.308

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Novel neurohumoral factors in congestive heart failure: adrenomedullin.

Authors:  J G Lainchbury
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

2.  An ontogenic study of adrenomedullin gene expression in the rat lung, adrenal, kidney, and heart.

Authors:  P F Wong; W S O; F Tang
Journal:  Endocrine       Date:  2011-11-01       Impact factor: 3.633

3.  Dysregulation of Cerebellar Adrenomedullin Signaling During Hypertension.

Authors:  Leticia Figueira; Anita Israel
Journal:  J Mol Neurosci       Date:  2017-06-26       Impact factor: 3.444

4.  Two molecular forms of adrenomedullin in congenital heart disease.

Authors:  K Watanabe; T Nishikimi; M Takamuro; K Yasuda; Y Ishikawa; S Tanabe; O Yamada; N Nagaya; H Matsuoka; K Kangawa; S Echigo
Journal:  Pediatr Cardiol       Date:  2003-09-04       Impact factor: 1.655

5.  Proadrenomedullin N-terminal 20 peptide inhibits adrenocorticotropin secretion from cultured pituitary cells, possibly via activation of a potassium channel.

Authors:  W K Samson; T C Murphy; Z T Resch
Journal:  Endocrine       Date:  1998-12       Impact factor: 3.925

Review 6.  Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.

Authors:  Toshihiro Kita; Kazuo Kitamura
Journal:  Hypertens Res       Date:  2022-01-06       Impact factor: 5.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.